4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-015031
CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $21.73 ($260,800)
- CHIEF SCIENTIFIC OFFICER acquired 12,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-05-29 | Exercise or conversion : show line 1 in the form 10b5-1 | +12,000 | $1.12 | $13,440 | 12,000 | D |
| 2024-05-29 | Sale : show line 2 in the form 10b5-1 | −9,877 | $21.56 | $212,988 | 2,123 | D |
| 2024-05-29 | Sale : show line 3 in the form 10b5-1 | −2,123 | $22.52 | $47,813 | 0 | D |
| Open-market sales · 12,000 sh · avg $21.73 · $260,800 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-05-29 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) | −12,000 | 206,550 | D |
Loading xslF345X05/form4-05312024_080541.xml…